These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9036301)

  • 1. [Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature].
    Sturm C
    Med Klin (Munich); 1996 Nov; 91(11):735-8. PubMed ID: 9036301
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
    Anderson KM; Bala MV; Weisman HF
    Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
    Mayosi BM; Latouf SE; Commerford PJ
    S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen.
    Rinfret S; Kennedy WA; Lachaine J; Lemay A; Rodés-Cabau J; Cohen DJ; Costerousse O; Bertrand OF
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1011-9. PubMed ID: 20965458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
    [No Abstract]   [Full Text] [Related]  

  • 6. Outpatient percutaneous coronary interventions: hospital and health system costs saving while maintaining patient safety.
    Popescu AM; Weintraub WS
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1020-1. PubMed ID: 20965459
    [No Abstract]   [Full Text] [Related]  

  • 7. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
    van Hout BA; Bowman L; Zelinger DJ; Simoons ML
    Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elective or selective use of abciximab?
    Butler R; Samani NJ
    Lancet; 2000 Feb; 355(9205):755. PubMed ID: 10703832
    [No Abstract]   [Full Text] [Related]  

  • 9. Murmurs from the heart (or why the stethoscope is not an economic tool).
    Aristides M; Gliksman M
    Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073
    [No Abstract]   [Full Text] [Related]  

  • 10. Double vessel occlusions after balloon angioplasty treated by stenting and subsequently by abciximab infusion.
    Bertrand OF; Meerkin D; de Guise P; Crépeau J; Bourassa MG
    Can J Cardiol; 2000 Jan; 16(1):83-5. PubMed ID: 10653937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and outcomes analysis of abciximab use in a community teaching hospital.
    Abernathy GB; Hewitt KK
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S35-7. PubMed ID: 9872696
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of abciximab versus tirofiban on hospital length of stay for PCI patients.
    Lage MJ; Barber BL; McCollam PL; Bala M; Scherer J
    Catheter Cardiovasc Interv; 2001 Mar; 52(3):298-305. PubMed ID: 11246240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of eptifibatide and abciximab with decision analysis.
    Wong DH
    Am J Health Syst Pharm; 2001 Aug; 58(15):1432-6. PubMed ID: 11494790
    [No Abstract]   [Full Text] [Related]  

  • 14. Enthusiasm, reality, and cost-effectiveness analysis.
    Brophy JM; Sleight P
    Heart; 1998 Jan; 79(1):9-10. PubMed ID: 9505910
    [No Abstract]   [Full Text] [Related]  

  • 15. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
    Oh PI; Cohen EA; Mittmann N; Seung SJ
    Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abciximab therapy in percutaneous intervention: economic issues in the United States.
    Goklaney AK; Murphy JD; Hillegass WB
    Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
    van Hout BA; Bowman L; Zelinger DJ; Simoons ML
    Am Heart J; 1998 Apr; 135(4):S98-106. PubMed ID: 9539500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands.
    van Hout BA; Simoons ML
    Eur Heart J; 1995 Nov; 16 Suppl L():81-5. PubMed ID: 8869024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing and administration of ReoPro (c7E3 Fab).
    Tcheng JE
    J Invasive Cardiol; 1994; 6 Suppl A():29A-33A; discussion 51A-54A. PubMed ID: 10155091
    [No Abstract]   [Full Text] [Related]  

  • 20. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab.
    Alvarez JM
    J Thorac Cardiovasc Surg; 1998 Feb; 115(2):472-3. PubMed ID: 9475547
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.